Burrill, which has 24 healthcare companies as limited partners in its venture capital funds, adds state partner to treble NewBridge Pharmaceuticals' B round to $12m.

New York-listed medical device company Boston Scientific has agreed to acquire one of its corporate venturing portfolio companies, Asthmatx, for initial $193.5m outlay.

Detlef Albrecht promoted to executive president of Sorbent Therapeutics as its finishes its series B round.

Abbott Laboratories joins venture consortium's $20.6m investment in Voyage Medical.

Nick Leschly, partner of Third Rock Ventures, has been appointed the company's president and chief executive as Genetix Pharmaceuticals rebrands itself Bluebird Bio.

Safeguard Scientifics joins consortium investing $18m in Good Start Genetics.

Newswire Bloomberg quotes Eli Lilly executive as saying it would commit up to 20% of each of the three venture funds that could raise $250m each.

St Jude buys 19% of CardioMems and the right to buy the company for $375m.

GlaxoSmithKline's corporate venturing division SR One and Biogen Idec's $200m New Ventures unit alongside undisclosed other investors have bolstered iPierian's series B round.